香港股市 已收市

PolyPeptide Group AG (PPGN.SW)

Swiss - Swiss 延遲價格。貨幣為 CHF。
加入追蹤清單
73.90+6.15 (+9.08%)
收市價: 05:31PM CEST

PolyPeptide Group AG

Dammstrasse 19
Zug 6300
Switzerland
41 41 723 20 34
https://www.polypeptide.com

版塊Healthcare
行業Drug Manufacturers—Specialty & Generic
全職員工1,101

高階主管

名稱標題支付行使價出生年份
Dr. Raymond De Vre Ph.D.Chief Exec. Officer1968
Mr. Jan Fuhr MillerChief Financial Officer1970
Mr. Daniel LasanowDirector of Global Operations1962
Mr. Michael StaheliHead of Investor Relations & Corp. Communications
Ms. Christina Del VecchioGen. Counsel & Corp. Sec.1978
Mr. Neil James ThompsonDirector of Global Sales & Marketing1972
Monika CasanovaChief HR Officer
Mr. Jan ChristensenExec. Officer1961
截止 為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 CHF。

描述

PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.

公司管治

截至 無 止,PolyPeptide Group AG 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。